News January 8, 2021 Soricimed and Orano Med Announce Collaboration to Develop New Targeted Cancer Treatments
News December 17, 2020 Soricimed to Investigate the Potential Benefit of SOR-C13 in the Treatment of COVID-19
News September 29, 2020 Soricimed Continues Critical Research Thanks to Support from the Government of Canada
News June 9, 2020 Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial of SOR-C13
News February 7, 2020 Soricimed Announces Completion of First Cohort in Investigator-Initiated Phase 1b Clinical Trial of SOR-C13
News December 3, 2019 Soricimed to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
News November 26, 2019 Soricimed Announces Journal of Cancer Publication Identifying TRPV6 as a Promising Target for Cancer Therapy
News November 1, 2019 BioTuesdays video of our primary focus area, targeted drug candidates for the treatment of solid-tumor cancers.
News October 2, 2019 Chief Scientific Officer, Professor Jack Stewart discusses focus on ovarian, prostate and pancreatic cancers.
News October 2, 2019 Professor Jack Stewart, Chief Scientific Officer, explains the mechanism of action of Soricimed's lead drug candidate, SOR-C13.
News October 2, 2019 Chief Scientific Officer, Professor Jack Stewart, provides background on the investigator initiated clinical trial of SOR-C13 in late-stage pancreatic cancer.
News September 24, 2019 Soricimed Announces Initiation of Patient Dosing for First Cohort in Investigator-Initiated Phase 1b Clinical trial of SOR-C13
News September 5, 2019 Soricimed and Image Analysis Group Partner to Validate Predictive Imaging Markers for SOR-C13 Treatment Response in Solid Cancer Tumors
News August 6, 2019 Soricimed Announces Investigator Initiated Phase 1b Clinical trial of its Lead Drug Candidate in Late-Stage Pancreatic Cancer
News October 31, 2018 Soricimed Publishes New Research Validating TRPV6 as a Therapeutic Target for Ovarian Cancer
News March 19, 2018 Soricimed Announces the Appointment of Dr. Marc Rubin and Mr. Vaughn Embro-Pantalony to Board of Directors
/img/newsandevents/San_Fran_thumb.jpg Events September 20, 2017 World ADC San Francisco 2017, San Francisco, CA
/img/newsandevents/San_Diego_thumb.jpg Events June 4, 2017 2017 BIO International Convention, San Diego, CA
/img/newsandevents/San_Fran_thumb.jpg Events October 18, 2016 BIO Investor Forum 2016, San Francisco, CA
News September 27, 2016 Soricimed’s SOR-C13 Granted Orphan Drug Designation for Pancreatic Cancer by the U.S. FDA
/img/newsandevents/San_Fran_thumb.jpg Events June 9, 2016 2016 BIO International Convention, San Francisco, CA
/img/newsandevents/San_Diego_thumb.jpg Events May 12, 2016 ACCR (American Academy for Cancer Research) Pancreatic Cancer: Advances in Science and Clinical Care, Orlando, Florida
/img/newsandevents/New_Orleans_thumb.jpg Events April 16, 2016 AACR (American Academy for Cancer Research), New Orleans, Louisiana
News April 12, 2016 Soricimed Announces Presentations at the Upcoming American Association of Cancer Research (AACR) Annual Meeting
News March 8, 2016 Soricimed Granted Orphan-Drug Designation from the U.S. FDA for Treatment of Ovarian Cancer
News February 23, 2016 Soricimed Announces Positive Top-Line Results in Phase 1 Trial of First-in-Class Peptide SOR-C13 in Subjects with Advanced Solid Tumour Cancers
News January 26, 2016 Soricimed Welcomes Bob Cory, PhD, to Executive Team and Appoints Tom Reeves to Chair
News May 6, 2015 Targeting TRPV6 with Soricimed’s Novel SOR-C13 Inhibits Tumour Growth in Breast and Ovarian Cancer Models
News May 6, 2015 Soricimed’s Findings Support TRPV6 as a Novel and Significant Biomarker for Ovarian Cancer-Targeted Therapies and Diagnostics
News November 4, 2013 Toxicology Study of Soricimed’s Anti-Cancer Agent Presented at ACT Conference in San Antonio
News October 15, 2013 Soricimed Shows Promise In Treating Breast and Ovarian Cancer With Peptide-Paclitaxel Conjugate
/img/newsandevents/San_Fran_thumb.jpg Events September 20, 2013 World ADC San Francisco 2013, San Francisco, CA
News July 16, 2013 Soricimed Biopharma Inc. Appoints Tom Reeves to Board of Directors and Welcomes Mario Thomas, PhD, to the Executive Team
News May 28, 2013 Jack Stewart, Chairman and Chief Scientific Officer of Soricimed, speaks on proof-of-concept study results at annual cancer research workshop.
News May 23, 2013 Soricimed Biopharma Inc. Announces U.S. Trial Site for Phase I Clinical Trial of New Cancer Drug, SOR-C13
News March 19, 2013 Soricimed’s Peptides Used to Detect Ovarian and Prostate Cancer - Proof of Concept Published in Peer-Reviewed Publication
